Psilocybin shows to be effective treatment for depression and anxiety

In a randomized, double-blind clinical trial, consisting of 56 terminal cancer patients with significant depression and death anxiety, psilocybin has been attributed to an increase in quality of life and mitigation of depressive symptoms. This study, from Johns Hopkins Medical Center, is significant, in that most studies into psilocybin for this purpose have focused on microdoses, whereas this study correlates similar outcomes for those who ingest high doses, in addition to microdoses. 80 % in the study reported fewer depressive symptoms after one treatment, and 78% were reported to be in remission after 6 months from anxiety and 83% in remission from clinical depression diagnosis after 6 months.



Griffiths, R., et al. (2016). "Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial." Journal of Psychopharmacology, 30(12), 1181–1197. DOI: 10.1177/0269881116675513